Why the study?
Is ARO-APOC3 safe and well-tolerated in healthy volunteers and patients with elevated triglycerides?
RCT (n=112)
Is ARO-APOC3 safe and well-tolerated in healthy volunteers and patients with elevated triglycerides?
In a phase I trial, ARO-APOC3 appeared safe with no adverse effects leading to study drug discontinuation, supporting further investigation for triglyceride lowering.
report on safety and efficacy of a strategy targeting apolipoprotein C-III (APOC3) using a silencing ribonucleic acid (RNA; ARO-APOC3). In a phase I trial comprising 52 healthy volunteers (triglycerides [TG], >80 mg/dl), 40 patients with hypertriglyceridemia (TG, >300 mg/dl), and 20 patients with chylomicronemia (TG, >880 mg/dl), ARO-APOC3 or placebo was administered subcutaneously either once or twice, with doses given on days 1 and 29. The primary goal was to examine the safety of ARO-APOC3. Injection site reactions were the most commonly observed adverse clinical event; no adverse effects led to discontinuation of the study drug.
No takes yet. Share an insight, caveat, or question.
Kraaijenhof et al. (2023) conducted an RCT in Hypertriglyceridemia and chylomicronemia (n=112). ARO-APOC3 vs. Placebo was evaluated on Safety.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: